Stockscreener 앱 받기
529.69
1.66%
8.66
시간 외 거래:
540.01
10.32
+1.95%
전일 마감가:
$521.03
열려 있는:
$514.45
하루 거래량:
1.24M
Relative Volume:
0.91
시가총액:
$134.26B
수익:
$12.34B
순이익/손실:
$4.34B
주가수익비율:
31.40
EPS:
16.8685
순현금흐름:
$3.71B
1주 성능:
+0.99%
1개월 성능:
+0.38%
6개월 성능:
+23.14%
1년 성능:
+25.40%
1일 변동 폭
$513.37
$534.94
1주일 범위
$509.20
$534.94
52주 변동 폭
$403.16
$560.25
버텍스 파마슈티컬 Stock (VRTX) Company Profile
명칭
Vertex Pharmaceuticals Inc
전화
(617) 341-6393
주소
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
529.69 | 134.26B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
214.16 | 85.50B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
813.27 | 83.73B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.76 | 56.08B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
373.36 | 42.24B | 5.76B | 514.49M | 1.10B | 4.4813 |
버텍스 파마슈티컬 Stock (VRTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-09-21 | 개시 | Leerink Partners | Outperform |
| 2026-09-02 | 재개 | Morgan Stanley | Overweight |
| 2026-05-27 | 재개 | Truist | Buy |
| 2026-03-18 | 업그레이드 | Maxim Group | Hold → Buy |
| 2026-03-10 | 개시 | Jefferies | Buy |
| 2026-03-10 | 재확인 | Oppenheimer | Outperform |
| 2026-02-13 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2026-01-22 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-01-12 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2026-01-07 | 재개 | UBS | Buy |
| 2026-01-06 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-12-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-09-25 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | 개시 | Raymond James | Mkt Perform |
| 2025-08-06 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-02-12 | 업그레이드 | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | 업그레이드 | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | 재확인 | H.C. Wainwright | Buy |
| 2024-12-19 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-12-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-11-14 | 개시 | Citigroup | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Perform |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-08-05 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-06-27 | 개시 | Redburn Atlantic | Buy |
| 2024-04-11 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2024-02-06 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-02-02 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2024-01-31 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | 다운그레이드 | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | 개시 | William Blair | Outperform |
| 2023-05-04 | 재개 | Piper Sandler | Overweight |
| 2023-03-21 | 개시 | Bernstein | Outperform |
| 2023-01-18 | 개시 | Canaccord Genuity | Hold |
| 2023-01-17 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-06-01 | 업그레이드 | Maxim Group | Hold → Buy |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-05-06 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | 재확인 | JP Morgan | Overweight |
| 2022-01-27 | 재확인 | Morgan Stanley | Underweight |
| 2022-01-27 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-01-27 | 재확인 | Stifel | Hold |
| 2022-01-27 | 재확인 | Wolfe Research | Outperform |
| 2022-01-20 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-11-19 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | 재개 | Wolfe Research | Outperform |
| 2021-07-01 | 개시 | Raymond James | Mkt Perform |
| 2021-06-11 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-30 | 개시 | Daiwa Securities | Outperform |
| 2020-11-30 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | 개시 | Bernstein | Outperform |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-07-31 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-28 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-31 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-09-03 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-08-01 | 다운그레이드 | Needham | Buy → Hold |
| 2019-05-23 | 재개 | Citigroup | Buy |
| 2019-05-21 | 개시 | Credit Suisse | Outperform |
| 2019-04-12 | 개시 | Evercore ISI | In-line |
| 2019-03-26 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | 다운그레이드 | Maxim Group | Buy → Hold |
모두보기
버텍스 파마슈티컬 주식(VRTX)의 최신 뉴스
Is Povetacicept The Next Chapter For Vertex Pharmaceuticals (NASDAQ:VRTX)? - Kalkine Media
Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue - The Motley Fool
Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue - The Motley Fool
Vertex Pharmaceuticals (VRTX) CEO Jeff Leiden's Leadership Journ - GuruFocus
Scotiabank keeps USD 558.00 target for Vertex Pharma stock - ad-hoc-news.de
Which Biotech ETF Is the Better Buy: VanEck’s BBH or Invesco’s Factor-Driven PBE? - The Motley Fool
Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards? - Zacks Investment Research
Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards? - TradingView
Vertex Pharmaceuticals advances povetacicept: what it means for Vertex Pharmaceuticals stock - ad-hoc-news.de
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why - Zacks Investment Research
BHC Q3 Earnings Preview: Here's What You Should Know - Zacks Investment Research
Vertex Pharmaceuticals shares may move 4.3% on earnings By Investing.com - Investing.com South Africa
The $500 Million Non-CF Factor Vertex Investors Can’t Ignore on Nov. 2 - 24/7 Wall St.
Vertex Pharmaceuticals shares may move 4.3% on earnings - Investing.com
Vertex Pharmaceuticals shares may move 4.3% on earnings By Investing.com - Investing.com UK
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy? - Zacks Investment Research
Vertex Pharma publishes kidney results as Vertex Pharma stock trades at EUR 469.45 - ad-hoc-news.de
I'm Not Worried About a Stock Market Crash, and It's Because I'm Making This 1 Investing Move - The Motley Fool
VanEck Biotech vs. Invesco Healthcare: Which ETF Offers More Potential for Long-Term Growth? - The Motley Fool
Vertex Pharmaceuticals Gets 96% of Product Sales From Treatments for 1 Disease. Here's Why That's About to Change. - The Motley Fool
Vertex Pharmaceuticals Gets 96% of Product Sales From Treatments for 1 Disease. Here's Why That's About to Change. - The Motley Fool
Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase III - Yahoo Finance
Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Society of Nephrology (ASN) Kidney Week 2026Slideshow (NASDAQ:VRTX) 2026-10-23 - Seeking Alpha
Vertex reports positive IgAN trial data, FDA decision due Nov. 30 - Investing.com Australia
Vertex Stock Looks Expensive. Does It Get Cheaper Ahead? - Trefis
Cystic Fibrosis Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - StreetInsider
Vertex Pharmaceuticals Incorporated Estimates – LSE:0QZU - TradingView
Why Healthcare ETFs Are Hovering Around One-Year Highs - Zacks Investment Research
Invesco Pharmaceuticals ETF vs. iShares Biotechnology ETF: Which Is the Better Buy? - The Motley Fool
Form 4 Vertex Pharmaceuticals Inc: Daniel J. Brennan (Director) For: 20 October - Investing.com UK
Vertex Pharmaceuticals Incorpor (VRTX) Stock Forecasts - Yahoo Finance
VERTEX PHARMACEUTICALS INC / MA Initial Statement of Beneficial Ownership - Stock Titan
Vertex Pharmaceuticals Inc. Research & Ratings | VRTX - Barron's
Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy? - The Motley Fool
Vertex Pharma stock at EUR 464.48 ahead of the Xetra open: biotech group - AD HOC NEWS
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Vertex Pharmaceuticals’ New Drugs Are Gaining Ground. Is That Enough for Investors? - Yahoo Finance
Vertex Pharma stock: Third-quarter results arrive November 2 for Vertex Pharma stock - AD HOC NEWS
Vertex appoints Daniel Brennan. Vertex Pharma stock has USD 130.4 billion value - AD HOC NEWS
Vertex Pharma stock pre-market at EUR 456.53 ahead of Xetra open - AD HOC NEWS
Vertex Appoints Daniel Brennan to its Board of Directors - BioSpace
Vertex Pharmaceuticals (VRTX) Expands Board to Eleven Members wi - GuruFocus
Why Should You Think About Vertex Differently Now? - Yahoo Finance
Form 8K Vertex Pharmaceuticals Inc For: 20 October By Investing.com - Investing.com Nigeria
AbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know - Zacks Investment Research
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
Vertex Pharmaceuticals appoints Daniel Brennan to board of directors - Investing.com
Vertex Pharmaceuticals appoints Daniel Brennan to board, joins Audit and Finance Committee - TradingView
Vertex Pharmaceuticals Incorporated Announces Appointment of Daniel Brennan as Member of the Board of Directors, Audit and Finance Committee - www.marketscreener.com
버텍스 파마슈티컬 (VRTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
버텍스 파마슈티컬 주식 (VRTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Tatsis Ourania | EVP, Chief Reg. & Quality Off. |
Jul 02 '26 |
Sale |
524.99 |
1,500 |
787,485 |
45,321 |
| McKechnie Duncan | EVP, Chief Commercial Officer |
Jul 02 '26 |
Sale |
519.00 |
1,541 |
799,779 |
11,001 |
| Tatsis Ourania | Officer |
Jul 02 '26 |
Proposed Sale |
524.99 |
1,500 |
787,485 |
0 |
| McKechnie Duncan | Officer |
Jul 02 '26 |
Proposed Sale |
519.00 |
1,541 |
799,779 |
0 |
| Liu Joy | EVP and Chief Legal Officer |
Jul 01 '26 |
Sale |
502.71 |
828 |
416,244 |
19,131 |
| Liu Joy | Officer |
Jul 01 '26 |
Proposed Sale |
502.71 |
828 |
416,244 |
0 |
| Bozic Carmen | EVP and CMO |
Jun 26 '26 |
Sale |
482.50 |
596 |
287,570 |
15,337 |
| Bozic Carmen | Officer |
Jun 26 '26 |
Proposed Sale |
482.50 |
596 |
287,570 |
0 |
| Bozic Carmen | Officer |
Jun 18 '26 |
Proposed Sale |
462.17 |
1,020 |
471,413 |
0 |
| Bozic Carmen | EVP and CMO |
Jun 18 '26 |
Sale |
462.17 |
1,020 |
471,413 |
15,933 |
2.98%
0.35%
자본화:
|
볼륨(24시간):